This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Huntington Ingalls Industries (HII) reports $3.1B Q2 revenue, backlog at $56.9B, with enhanced free cash flow guidance.

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...